Director Richard Newcomb Stillwell buys 5,000 shares of TNXP at $11.65; stock down -83.6% from 52-week high amid unprofitable operations.
Richard Newcomb Stillwell, a director at Tonix Pharmaceuticals, purchased 5,000 shares at $11.65 on 2026-06-08, establishing a position in a company currently trading at $11.46—83.6% below its 52-week high of $69.97. The company generated $6.9M in quarterly revenue but posted a net loss of $40.2M, indicating significant burn relative to sales despite 29.8% annual revenue growth. The stock has declined 18.7% over 30 days and 18.0% over 90 days, reflecting sustained pressure on the equity. This purchase by a director during a period of substantial price deterioration occurs in the context of an unprofitable operation and warrants examination of the director's historical transaction pattern and the company's path to profitability.